Clinical Trial Update: A Phase 1 Study to Assess STP938 as a Monotherapy in Adults With High Risk Essential Thrombocythaemia [Phase 1]

View source ↗

Summary

Phase 1 study of STP938 as monotherapy for high-risk Essential thrombocythemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia

Drugs mentioned

• STP938

Snippet

Sponsor: Step Pharma, SAS | Conditions: Essential Thrombocythaemia | Phase 1 | Status: RECRUITING